Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zafgen's Beloranib data pushed back to 2016

This article was originally published in Scrip

Executive Summary

During a fourth quarter earnings call on 19 March, Zafgen announced that data from a clinical trial of its lead asset – being studied in a rare metabolic disease – would not be available until early 2016 instead of later this year, as initially promised. Beloranib is a treatment for Prader-Willi Syndrome (PWS) and Zafgen began enrolling patients for its Phase III trial in September 2014. Due to slower than expected enrollment in the trial, the company was forced to move back its projections for topline data expectations. Currently all 15 clinical trial sites in the US are enrolling and active with the expectation that 102 patients will be included in the trial. Beloranib could eventually be used as a treatment for the morbidly obese, but Zafgen has been studying the drug in smaller sub-populations in hopes of proving its safety and efficacy on a small biotech's budget. The obesity drug developer hosted an initial public offering last June and a follow-on offering in January, raising $230m total, to support its metabolic disease pipeline (scripintelligence.com, 21 April 2014).

You may also be interested in...



IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Zafgen Drops Beloranib, But Its New Focus Raises Doubts

The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.

Update: Ziopharm Study Death Not Due To Drug

The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132046

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel